You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍隨A股同業造好 威高股份、藥明系及信達生物漲5%-8%
內地醫藥生物板塊升1.4%(跑贏滬深股市半日升0.4%-0.9%)。本港醫藥股也普遍跑贏大市。信達生物(01801.HK)兩連升,最高見35.25元,創逾三個月高,現報34.9元,續升8%。威高股份(01066.HK)四連升兼創近三個月高,報9.21元,漲逾5%。康方生物(09926.HK)六連升,最高見26.8元,創逾五個月高,現報25.4元,續漲半成。 藍籌藥明生物(02269.HK)兩連升,最高見76.8元,回補2月8日部分下跌裂口,現報75.3元,續漲7.6%。藥明康德(02359.HK)續升6.8%報103.8元;藥明康德A(603259.SH)半日漲逾半成曾高見101元人民幣。 騰盛博藥(02137.HK)升5.7%報9.06元。康希諾(06185.HK)高見83.95元,現報83元,續彈3.2%;康希諾A(688185.SH)半日升逾半成曾高見202元。 藍籌中生製藥(01177.HK)高見4.75元創近三個月高,現報4.73元,續升5.1%。石藥(01093.HK)、 歌禮製藥(01672.HK)、君實生物(01877.HK)及金斯瑞生物(01548.HK)升逾2%-3%,後者最強曾高見28.45元,現報28.1元,續升3.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account